Odefsey (Emtricitabine, Tenofovir Alafenamide, Rilpivirine)

Odefsey is a fixed‑dose antiretroviral regimen that targets the HIV‑1 replication pathway.

• HIV‑1 infection (adults and adolescents): provides a complete, once‑daily regimen that suppresses viral load when combined with other antiretrovirals.
• Treatment‑naïve patients: offers a convenient single‑tablet option to achieve and maintain viral suppression.
• Patients switching from other regimens: facilitates a simplified dosing schedule while maintaining efficacy.

• Odefsey combines three agents that inhibit HIV replication at distinct stages: emtricitabine and tenofovir alafenamide are nucleoside/nucleotide reverse‑transcriptase inhibitors that block viral DNA synthesis, while rilpivirine is a non‑nucleoside reverse‑transcriptase inhibitor that binds to a separate site on the reverse‑transcriptase enzyme, preventing transcription of viral RNA.

Adverse reactions to Odefsey are reported across clinical studies and post‑marketing surveillance.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, usually transient.
• Headache: mild tension‑type headache.
• Fatigue: general tiredness.
• Insomnia: difficulty falling or staying asleep.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Severe hypersensitivity: rash with systemic involvement, possibly Stevens‑Johnson syndrome.
• Renal impairment: worsening kidney function, especially in patients with pre‑existing disease.
• Bone mineral density loss: decreased bone density with long‑term use.
• Lactic acidosis: rare metabolic acidosis with high lactate levels.
• QT prolongation: potential cardiac rhythm disturbance.

When prescribing Odefsey, clinicians should consider several safety aspects.

• Renal function assessment: evaluate baseline kidney function before initiation.
• Hepatic monitoring: check liver enzymes periodically, especially in patients with hepatitis.
• Pregnancy counseling: discuss potential risks and benefits with women of childbearing potential.
• Drug‑interaction review: assess concomitant medications for possible interactions.
• Adherence support: emphasize the importance of daily dosing for viral suppression.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Odefsey may interact with other medicines that affect its absorption, metabolism, or excretion.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce rilpivirine absorption.
• Proton pump inhibitors (e.g., omeprazole): lower rilpiviri ne levels.
• Rifampin and other strong CYP3A inducers: markedly decrease rilpivirine concentrations.

Moderate Interactions (Monitor Closely)

• H2‑blockers (cimetidine, ranitidine): may modestly reduce rilpivirine exposure.\n- Lipid‑lowering agents (statins such as rosuvastatin): increased statin exposure due to tenofovir alafenamide.
• Contraceptive hormones: potential reduction in hormonal efficacy.
• Warfarin: possible alteration of INR values.
• Methotrex ​